Pharmacological or genetic inhibition of Scn9a protects human and mouse beta cells while dampening insulin secretion in type 1 diabetes

Inhibiting the Na+ channel gene Scn9a reduces beta cell loss and diabetes incidence in NOD mice, highlighting its potential as a therapeutic target for type 1 diabetes.

• Why it matters: Preserving pancreatic beta cells is crucial for preventing or delaying type 1 diabetes, but the specific mechanisms and targets involved in beta cell survival remain unclear.
• What they did: The study used genetic knockout and pharmacological approaches to inhibit Scn9a in human and mouse beta cells, examining effects on cell function, survival, and diabetes development in NOD mice.
• The result: Inhibition of Scn9a decreased beta cell excitability, insulin secretion at high glucose, and notably reduced diabetes incidence, suggesting that targeting this channel could protect beta cells and mitigate disease progression.